Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BCPC
stocks logo

BCPC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
259.59M
+8.16%
1.285
+13.72%
266.86M
+6.52%
1.310
+7.38%
269.14M
+5.35%
1.370
+7.87%
Estimates Revision
The market is revising Upward the revenue expectations for Balchem Corporation (BCPC) for FY2025, with the revenue forecasts being adjusted by 0.8% over the past three months. During the same period, the stock price has changed by -4.85%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.8%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.49%
In Past 3 Month
Stock Price
Go Down
down Image
-4.85%
In Past 3 Month
Wall Street analysts forecast BCPC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCPC is 190.00 USD with a low forecast of 190.00 USD and a high forecast of 190.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BCPC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCPC is 190.00 USD with a low forecast of 190.00 USD and a high forecast of 190.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 153.350
sliders
Low
190.00
Averages
190.00
High
190.00
Current: 153.350
sliders
Low
190.00
Averages
190.00
High
190.00
H.C. Wainwright
Buy
maintain
$189 -> $190
2025-10-22
Reason
H.C. Wainwright
Price Target
$189 -> $190
2025-10-22
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Balchem to $190 from $189 and keeps a Buy rating on the shares. The firm remains confident in Balchem's long-term prospects following the Q3 beat. The company's sales performance and operational efficiency are driving growth, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$180 -> $189
2025-08-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$180 -> $189
2025-08-04
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Balchem to $189 from $180 and keeps a Buy rating on the shares. The company reported Q2 beat and its future growth should be driven by manufacturing expansion and anti-dumping measures, the analyst tells investors in a research note. The firm believes the European Commission's provisional anti-dumping duties on imports into the European Union of choline chloride originating in the People's Republic of China should improve the sales outlook of Balchem's choline-based products in Europe.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$190
2025-02-24
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$190
2025-02-24
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Balchem Corp (BCPC.O) is 28.24, compared to its 5-year average forward P/E of 33.22. For a more detailed relative valuation and DCF analysis to assess Balchem Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
33.22
Current PE
28.24
Overvalued PE
36.49
Undervalued PE
29.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
21.08
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
23.14
Undervalued EV/EBITDA
19.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.89
Current PS
0.00
Overvalued PS
5.51
Undervalued PS
4.28
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 2062.5% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BCPC News & Events

Events Timeline

(ET)
2025-10-21
07:02:06
Balchem announces Q3 adjusted EPS of $1.35, up from $1.13 a year ago
select
2025-07-31 (ET)
2025-07-31
07:06:10
Balchem reports Q2 adjusted EPS $1.27 vs $1.09 last year
select
2025-04-24 (ET)
2025-04-24
07:05:58
Balchem reports Q1 adjusted EPS $1.22 vs $1.03 last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
10-30Newsfilter
Balchem Corporation to Participate in Baird's 55th Annual Global Industrial Conference on November 12, 2025

  • Company Presentation: Balchem Corporation will present at Baird's 55th Annual Global Industrial Conference on November 12, 2025, featuring key executives including Ted Harris and Martin Bengtsson.

  • Business Segments: Balchem operates in three main segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, focusing on enhancing health and well-being through specialty ingredients.

[object Object]
Preview
9.5
10-21NASDAQ.COM
Reasons Behind Today's Surge in Balchem Stock

  • Record Sales Growth: Balchem reported a record third-quarter sales increase of 11.5% year over year, driven by its specialty nutrients and favorable trends in the food and nutrition markets.

  • Stock Performance: Following the sales report, Balchem's stock rose over 5% in the morning and remained up by 3.8% later in the day, although the stock has not performed significantly throughout the year.

  • Investment in Growth: The company is investing to double its domestic capacity for nutrient delivery technologies, anticipating strong returns from this expansion.

  • Analyst Recommendations: Despite the positive sales news, Balchem was not included in the Motley Fool Stock Advisor's list of the 10 best stocks to buy, which has historically provided high returns for investors.

[object Object]
Preview
9.5
10-21NASDAQ.COM
Blachem (BCPC) Reports Q3 Earnings Below Expectations

  • Earnings Performance: Blachem (BCPC) reported quarterly earnings of $1.35 per share, slightly missing the Zacks Consensus Estimate of $1.36, but showing an increase from $1.03 per share a year ago. The company has surpassed consensus EPS estimates only once in the last four quarters.

  • Revenue Growth: The company achieved revenues of $267.56 million for the quarter, exceeding the Zacks Consensus Estimate by 1.92% and up from $239.94 million year-over-year. Blachem has topped revenue estimates three times in the last four quarters.

  • Stock Outlook: Blachem shares have declined about 7.5% year-to-date, underperforming the S&P 500's 14.5% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Industry Context: The Chemical - Specialty industry, to which Blachem belongs, is currently ranked in the bottom 30% of Zacks industries, suggesting potential challenges ahead. Investors are advised to monitor earnings estimate revisions for insights into future stock performance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Balchem Corp (BCPC) stock price today?

The current price of BCPC is 153.35 USD — it has decreased -0.45 % in the last trading day.

arrow icon

What is Balchem Corp (BCPC)'s business?

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

arrow icon

What is the price predicton of BCPC Stock?

Wall Street analysts forecast BCPC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCPC is 190.00 USD with a low forecast of 190.00 USD and a high forecast of 190.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Balchem Corp (BCPC)'s revenue for the last quarter?

Balchem Corp revenue for the last quarter amounts to 267.56M USD, increased 11.51 % YoY.

arrow icon

What is Balchem Corp (BCPC)'s earnings per share (EPS) for the last quarter?

Balchem Corp. EPS for the last quarter amounts to 1.24 USD, increased 20.39 % YoY.

arrow icon

What changes have occurred in the market's expectations for Balchem Corp (BCPC)'s fundamentals?

The market is revising Upward the revenue expectations for Balchem Corporation (BCPC) for FY2025, with the revenue forecasts being adjusted by 0.8% over the past three months. During the same period, the stock price has changed by -4.85%.
arrow icon

How many employees does Balchem Corp (BCPC). have?

Balchem Corp (BCPC) has 1361 emplpoyees as of December 05 2025.

arrow icon

What is Balchem Corp (BCPC) market cap?

Today BCPC has the market capitalization of 4.97B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free